tirzepatide pancreatic cancer Possible pro-oncogenic effect of (TRZD) on the pancreas, Scientists have discovered that tirzepatide—an

High protein, low carb, & low sodium

10.1038/nm1168 85

If you accidentally hit a vein or muscle, dont worry

An exploratory DEXA analysis of the STEP 1 trial found that semaglutide produced a 9.7% reduction in total lean body mass over 68 weeks alongside a 19.3% reduction in total fat mass, meaning fat was lost at roughly twice the rate of lean tissue

Preliminary safety reporting indicated: GI adverse event profile consistent with Phase 2 data No new safety signals identified beyond those observed in earlier trials Discontinuation rates due to adverse events were comparable to other GLP-1 class trials Full adverse event tables from TRIUMPH-4 are expected with the peer-reviewed publication

Sustainability questions